Clinical trial • Phase III • Gastroenterology|Nephrology
ARGIPRESSIN for Liver transplantation | Acute kidney injury
Phase III trial of ARGIPRESSIN for Liver transplantation | Acute kidney injury.
Overview
- Trial Therapeutic Area
- Gastroenterology|Nephrology
- Trial Disease
- Liver transplantation | Acute kidney injury
- Trial Stage
- Phase III
- Drug Modality
- Peptide/protein/enzyme|Small molecule
Key dates
- Initial CTIS Submission Date
- 02-10-2023
- First CTIS Authorization Date
- 12-01-2024
Trial design
REVERPLEG 40 U.I./2 mL (argipressin) solution for infusion; max daily dose 86.4 U (route: intravenous). Comparator: NORADRENALINE VIATRIS 2 mg/ml (noradrenaline tartrate) solution for infusion; max daily dose 40 mg (route: intravenous).-controlled Phase III trial in France.
- Comparator
- REVERPLEG 40 U.I./2 mL (argipressin) solution for infusion; max daily dose 86.4 U (route: intravenous). Comparator: NORADRENALINE VIATRIS 2 mg/ml (noradrenaline tartrate) solution for infusion; max daily dose 40 mg (route: intravenous).
- Target Sample Size
- 304
Eligibility
Recruits 304 Vulnerable population not selected. Adults under guardianship or trusteeship and persons deprived of their liberty are explicitly excluded. Patients unable to give informed consent (language barrier) are excluded. All participants must receive clear information and give signed informed consent; subject information and consent documents for adults (L1_SIS and ICF adults, simplified SIS for patients awaiting transplants) are listed..
- Pregnancy Exclusion
- Pregnancy or breastfeeding
- Vulnerable Population
- Vulnerable population not selected. Adults under guardianship or trusteeship and persons deprived of their liberty are explicitly excluded. Patients unable to give informed consent (language barrier) are excluded. All participants must receive clear information and give signed informed consent; subject information and consent documents for adults (L1_SIS and ICF adults, simplified SIS for patients awaiting transplants) are listed.
Inclusion criteria
- {"criterion_text":"- Age ≥ 18 years"}
- {"criterion_text":"- Any adult patient with a scheduled liver transplantation"}
- {"criterion_text":"- All participants will need to be given clear information about the study and give signed informed consent"}
- {"criterion_text":"- Person affiliated to the Social Security"}
Exclusion criteria
- {"criterion_text":"- Super-emergency for liver transplantation or fulminant hepatitis"}
- {"criterion_text":"- Pregnancy or breastfeeding"}
- {"criterion_text":"- Patient listed for or receiving simultaneous liver-kidney transplantation (SLKT)"}
- {"criterion_text":"- Patients with end-stage renal disease (chronic eGFR < 15 mL/min/1.73 m2 or requiring extra-renal purification before liver transplantation"}
- {"criterion_text":"- Patient with epilepsy"}
- {"criterion_text":"- Hypersensitivity to arginine-vasopressin and to its excipients"}
- {"criterion_text":"- Patient refusal"}
- {"criterion_text":"- Patients for whom it is impossible to give informed consent (language barrier)"}
- {"criterion_text":"- Adults under guardianship or trusteeship, persons deprived of their liberty"}
- {"criterion_text":"- Patient enrolled in another interventional clinical study"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Stages of AKI according to AKI Network criteria (KDIGO score) during the first 7 postoperative days","definition_or_measurement_approach":"Measured as stages of acute kidney injury using AKI Network criteria (KDIGO score) during the first 7 postoperative days."}
Secondary endpoints
- {"endpoint_text":"- The number of packed red blood cells and fresh frozen plasma transfused intraoperatively and during the first 12 hours postoperatively","definition_or_measurement_approach":"Measured as count/units of packed red blood cells and fresh frozen plasma transfused intraoperatively and during the first 12 postoperative hours."}
- {"endpoint_text":"- The need for renal replacement for replacement therapy (RRT) in ICU","definition_or_measurement_approach":"Recorded need for renal replacement therapy (RRT) in intensive care unit."}
- {"endpoint_text":"- Average intraoperative norepinephrine concentrations","definition_or_measurement_approach":"Measured as average intraoperative concentrations of norepinephrine."}
- {"endpoint_text":"- Average intraoperative concentrations of other vasopressors and inotropes (Adrenalin, Dobutamine)","definition_or_measurement_approach":"Measured as average intraoperative concentrations of other vasopressors and inotropes (e.g., adrenaline, dobutamine)."}
- {"endpoint_text":"- Number of platelets transfused intraoperatively and during the first 12 hours postoperatively","definition_or_measurement_approach":"Measured as count/units of platelets transfused intraoperatively and during the first 12 postoperative hours."}
- {"endpoint_text":"- Amount of vascular filling solutions intraoperatively and during the first 12 hours postoperatively","definition_or_measurement_approach":"Measured as volume/amount of vascular filling solutions administered intraoperatively and during the first 12 postoperative hours."}
- {"endpoint_text":"- Sequential Organ Failure Assessment (score SOFA) on the third postoperative day","definition_or_measurement_approach":"Measured using the Sequential Organ Failure Assessment (SOFA) score on the third postoperative day."}
- {"endpoint_text":"- Number of days alive outside intensive care unit during the 30 day post-operation","definition_or_measurement_approach":"Measured as number of days alive and not in intensive care during the 30 days following operation."}
- {"endpoint_text":"- Mortality at 30 days","definition_or_measurement_approach":"All-cause mortality measured at 30 days post-operation."}
Recruitment
- Planned Sample Size
- 304
- Recruitment Window Months
- 25
- Consent Approach
- Adults must receive clear information and provide signed informed consent. Consent documents available for publication include L1_SIS-simplified for patients awaiting transplants and L1_SIS and ICF adults; documents and public materials are in French. Minors are excluded, so no assent procedures are described. Patients unable to give informed consent (language barrier) are excluded.
Geography
- Total Number Of Sites
- 9
- Total Number Of Participants
- 304
France
- Earliest CTIS Part Ii Submission Date
- 22-12-2023
- Latest Decision Or Authorization Date
- 19-12-2025
- Processing Time Days
- 728
- Number Of Sites
- 9
- Number Of Participants
- 304
Sites
- Site Name
- Assistance Publique Hopitaux De Paris
- Department Name
- Anesthésie-Réanimation
- Contact Person Name
- Daniel EYRAUD
- Contact Person Email
- daniel.eyraud@aphp.fr
- Site Name
- Hospices Civils De Lyon
- Department Name
- Anesthésie-Réanimation
- Contact Person Name
- Thomas SCHULZ
- Contact Person Email
- thomas.schulz@chu-lyon.fr
- Site Name
- Centre Hospitalier Universitaire De Bordeaux
- Department Name
- Anesthésie-Réanimation
- Contact Person Name
- Antoine DEWITTE
- Contact Person Email
- antoine.dewitte@chu-bordeaux.fr
- Site Name
- Centre Hospitalier Regional Universitaire De Tours
- Department Name
- Anesthésie-Réanimation
- Contact Person Name
- Eric LEVESQUE
- Contact Person Email
- e.levesque@chu-tours.fr
- Site Name
- Assistance Publique Hopitaux De Paris
- Department Name
- Anesthésie-Réanimation
- Contact Person Name
- Emmanuel WEISS
- Contact Person Email
- emmanuel.weiss@aphp.fr
- Site Name
- Assistance Publique Hopitaux De Paris
- Department Name
- Anesthésie-Réanimation
- Contact Person Name
- Jacques DURANTEAU
- Contact Person Email
- jacques.duranteau@aphp.fr
- Site Name
- University Hospital Of Clermont-Ferrand
- Department Name
- Anesthésie-Réanimation
- Contact Person Name
- Thomas GODET
- Contact Person Email
- tgodet@chu-clermontferrand.fr
- Site Name
- Centre Hospitalier Universitaire De Lille
- Department Name
- Anesthésie-Réanimation
- Contact Person Name
- Gilles LEBUFFE
- Contact Person Email
- gilles.lebuffe@chru-lille.fr
- Site Name
- Les Hopitaux Universitaires De Strasbourg
- Department Name
- Anesthésie-Réanimation
- Contact Person Name
- Baptiste LORDIER
- Contact Person Email
- baptiste.lordier@chru-strasbourg.fr
Sponsor
Primary sponsor
- Full Name
- Assistance Publique Hopitaux De Paris
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- REVERPLEG 40 U.I./2 mL, solution à diluer pour perfusion
- Active Substance
- ARGIPRESSIN
- Modality
- Peptide/protein/enzyme
- Routes Of Administration
- INTRAVENOUS
- Route
- INTRAVENOUS
- Authorisation Status
- Authorised
- Maximum Dose
- 86.4 U unit(s)
- Investigational Product Name
- NORADRENALINE VIATRIS 2 mg/ml SANS SULFITES, solution à diluer pour perfusion
- Active Substance
- NORADRENALINE TARTRATE
- Modality
- Small molecule
- Routes Of Administration
- INTRAVENOUS
- Route
- INTRAVENOUS
- Authorisation Status
- Authorised
- Maximum Dose
- 40 mg milligram(s)
Related trials
Other published trials that may interest you.
- METHYLPREDNISOLONE for Fulminant myocarditis
- AMIKACIN SULFATE for Sepsis | Neutropenia
- BEVACIZUMAB for Advanced hepatocellular carcinoma|Liver transplant recipient
- ISATUXIMAB for Acute lymphoblastic leukaemia | T-lymphoblastic lymphoma
- piperacillin sodium, tazobactam sodium for Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae severe infection